-
Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
•
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49% year-on-year (YOY) increase in revenues, reaching RMB 143 million (USD 19.6 million). This growth was primarily driven by product sales and commercial cooperation. Olverembatinib’s Market Performance and Upcoming ApprovalsAscentage Pharma’s first marketed product, olverembatinib, generated…
-
Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization
•
The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE) respiratory syncytial virus (RSV) vaccine, Abrysvo, for the prevention of lower respiratory tract disease (LRTD) and severe LRTD in infants through active immunization of pregnant women between 32 and 36 weeks of gestation. This marks…
-
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
•
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE: JNJ) teclistamab has been granted priority review for the treatment of recurrent or refractory multiple myeloma in China. The drug is being considered for conditional approval due to its breakthrough therapy designation (BTD) status, given…
-
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
•
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38 million) for the first half of 2023, marking a 21.7% increase year-on-year. The significant growth was primarily driven by Ritonavir, which contributed RMB 44.17 million, representing a substantial 6291.8% YOY increase. Ritonavir’s Impact and Pfizer…
-
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
•
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its audited interim financial report for the period ended June 30, 2023. The company reported revenues of RMB 820 million (USD 112 million), marking a significant increase of 264.6% year-on-year (YOY). This period also saw the…
-
Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
•
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by Amgen (NASDAQ: AMGN) for the full registration of its pioneering KRASG12C inhibitor, Lumakras (sotorasib), in October this year. The treatment targets locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). Amgen announced this…
-
AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga (dapagliflozin), provides significant clinical benefits in patients with heart failure (HF) with preserved ejection fraction (pEF) and chronic obstructive pulmonary disease (COPD). This announcement highlights the potential of Forxiga in treating these conditions and underscores…
-
NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments
•
The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have passed the preliminary formal review stage for potential inclusion in this year’s adjustment to the National Reimbursement Drug List (NRDL). The public feedback window is open from August 18 to 24, 2023, allowing stakeholders to…
